TY - JOUR
T1 - Drug Insight
T2 - Gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy
AU - Loriot, Yohann
AU - Perlemuter, Gabriel
AU - Malka, David
AU - Penault-Lorca, Frédérique
AU - Boige, Valérie
AU - Deutsch, Eric
AU - Massard, Christophe
AU - Armand, Jean Pierre
AU - Soria, Jean Charles
PY - 2008/5
Y1 - 2008/5
N2 - Recent advances in the understanding of molecular mechanisms of cancer have led to the development of novel compounds that target specific cancer pathways. These drugs encompass monoclonal antibodies and tyrosine and non-tyrosine kinase inhibitors, and have been approved by the FDA and the European Medicines Agency, among others, for cancer treatment. These agents are associated with several toxic effects including potentially unacceptable gastrointestinal adverse effects. Diarrhea and hepatotoxicity, the most common adverse events experienced with these treatments, can frequently lead to treatment discontinuation and consequently decreased cancer control. We review the incidence and clinical patterns of the gastrointestinal and hepatic toxic effects induced by the main molecular-targeted therapies and propose some hypotheses for the causes of each adverse event.
AB - Recent advances in the understanding of molecular mechanisms of cancer have led to the development of novel compounds that target specific cancer pathways. These drugs encompass monoclonal antibodies and tyrosine and non-tyrosine kinase inhibitors, and have been approved by the FDA and the European Medicines Agency, among others, for cancer treatment. These agents are associated with several toxic effects including potentially unacceptable gastrointestinal adverse effects. Diarrhea and hepatotoxicity, the most common adverse events experienced with these treatments, can frequently lead to treatment discontinuation and consequently decreased cancer control. We review the incidence and clinical patterns of the gastrointestinal and hepatic toxic effects induced by the main molecular-targeted therapies and propose some hypotheses for the causes of each adverse event.
UR - http://www.scopus.com/inward/record.url?scp=42649121962&partnerID=8YFLogxK
U2 - 10.1038/ncponc1087
DO - 10.1038/ncponc1087
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 18349858
AN - SCOPUS:42649121962
SN - 1743-4254
VL - 5
SP - 268
EP - 278
JO - Nature Clinical Practice Oncology
JF - Nature Clinical Practice Oncology
IS - 5
ER -
